Kelaisi is an IVD instrument CDMO supplier offering customized development products and services across the full lifecycle, including whole‑machine development, core‑module development, design transfer, product registration, precision manufacturing, and after‑sales service. The company recently completed a nearly ¥100 million Series B financing. The round was led by 鲁信创投 with participation from 翰驰创投. Proceeds will be used to accelerate commercialization of its full line of instruments, including chemiluminescence, immunofluorescence, flow fluorescence, and mass‑spectrometry front‑end (pre‑processing) solutions. Kelaisi aims to provide domestic and international customers with ultra‑stable, high‑performance, cost‑effective products and CDMO services. The company stated an ambition to become an industry‑leading independent IVD instrument brand and a global CDMO supplier.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2024